ReviewFrontiers in cellular and infection microbiology2026
Periodontitis as a potential amplifier of diabetes-related genitourinary complications: evidence gradients and mechanistic insights into the inflammation-microvascular injury axis.
Review in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Periodontitis is increasingly recognized as a chronic systemic inflammatory burden that may be associated with greater vulnerability to selected diabetes-related genitourinary complications through overlapping inflammatory and microvascular pathways. This review integrates current epidemiological, mechanistic, and clinical evidence and proposes a conceptual "oral-metabolic-genitourinary axis" to describe potential links between periodontal inflammation and diabetic kidney disease (DKD), diabetes-related erectile dysfunction (ED), and recurrent urinary tract infections (UTIs). Available evidence is strongest for renal endpoints: observational studies and recent cohort data suggest associations between periodontitis and albuminuria, renal function decline, or dialysis risk in patients with type 2 diabetes. In contrast, evidence for ED and recurrent UTIs remains limited, with much of the support derived from mechanistic inference and indirect clinical observations. The proposed biologically plausible pathways include amplification of chronic low-grade systemic inflammation, endothelial and microvascular dysfunction, oxidative stress, advanced glycation end products-receptor for advanced glycation end products (AGE-RAGE) signaling, and microbiome interactions involving the oral-gut-genitourinary axis. These proposed associations and pathways may be modified or intensified by poor glycemic control, obesity, smoking, vitamin D deficiency, and gut dysbiosis. Clinically, periodontal therapy has been associated with improved glycemic control and may improve selected inflammatory or renal-related surrogate indicators, suggesting that oral health management could be considered a supportive component of multidisciplinary diabetes care. Overall, periodontitis is best viewed at present as a plausible amplifying factor rather than a confirmed independent cause of these outcomes, and this hypothesis requires confirmation in large prospective cohorts, randomized trials, and multi-omics studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.